Mentions in press and media 19
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 17, 2026 | Sarcomatrix Therapeutics Appoints Dr. Jeff Myers as Chief Medical Officer | Experienced biopharmaceutical executive and former cardiothoracic surgeon joins company as lead candidate S-969 advances toward IND submission RENO, NV, UNITED STATES, July 17, 2026 /EINPresswire.com/ -- Sarcomatrix Therapeutics, a biopharm... |
| Jul 15, 2026 | Sarcomatrix Therapeutics Corp. Opens Seed+ Investment Round to Accredited Investors on the KoreInside Platform | Preclinical-stage Nevada biotech funds its oral, mutation-agnostic Duchenne muscular dystrophy program toward a 2027 IND filing and first-in-human dosing. This round funds the next stage of our lead program as we move to first-in-human stud... |
| Jun 22, 2026 | Sarcomatrix Therapeutics Engages PatentVest to Strengthen IP Strategy for Lead Cardiomyopathy Program | Sarcomatrix, Inc Logo Integrated IP intelligence, strategy, and legal execution designed to strengthen enterprise value ahead of IND RENO, NV, UNITED STATES, June 22, 2026 /EINPresswire.com/ -- Sarcomatrix Therapeutics, Corp., a preclinical... |
| Jun 17, 2026 | Biotech Founder David Craig Releases The New Rules of Biotech: A Founder’s Guide to Building Great Companies | Sarcomatrix, Inc Logo New book draws on four decades of biotechnology experience to help founders, investors and operators navigate today’s evolving capital and regulatory landscape. RENO, NV, UNITED STATES, June 17, 2026 /EINPresswire.com/... |
| Jun 16, 2026 | Sarcomatrix Therapeutics Named Seed-Stage Finalist at BIO International Convention's Start-Up Stadium 2026 | Sarcomatrix, Inc Logo Clinical-stage biotechnology company advancing therapies for neuromuscular diseases selected to present before leading global investors and strategic partners RENO, NV, UNITED STATES, June 16, 2026 /EINPresswire.com/ -... |
| Mar 31, 2026 | Sarcomatrix Therapeutics Launches SarcoVista™ AI Platform as Lead Candidate S-969 Advances Toward First-in-Human Studies | Platform leverages muscle biology to de-risk development and identify new therapeutic targets ahead of clinical entry RENO, NV, UNITED STATES, March 31, 2026 /EINPresswire.com/ -- Sarcomatrix Therapeutics (“Sarcomatrix” or the “Company”), a... |
| Apr 9, 2025 | Sarcomatrix Renews United States Orphan Drug Designation for LAMA2-Related Muscular Dystrophy Program | Sarcomatrix Therapeutics Logo RENO, NV, UNITED STATES, April 9, 2025 /EINPresswire.com/ -- Sarcomatrix Therapeutics, a privately held biopharmaceutical company advancing transformative therapies for severe muscle diseases, today announced t... |
| Feb 7, 2025 | Sarcomatrix Therapeutics to Present Advances in Muscle Disease Drug Development at 2025 BIO CEO & Investor Conference | Sarcomatrix Therapeutics, Corp Logo Company Prepares for Phase 1 Clinical Trials of Lead Candidate S-969 in 2025 Our robust preclinical data, coupled with a clear regulatory strategy and growing investor confidence, positions 2025 as a land... |
| Jan 6, 2025 | Sarcomatrix to Present at Three Major Events During JPM Week 2025 in San Francisco | Saving Lives by Restoring Muscles RENO, NV, UNITED STATES, January 6, 2025 /EINPresswire.com/ -- Reno, NV – January 6, 2025 – Sarcomatrix Therapeutics, a pioneering biotech company advancing innovative therapies for muscle diseases, is prou... |
Show more
Reviews 0
FAQ about Sarcomatrix Therapeutics, Corp.
What has the press written about Sarcomatrix Therapeutics, Corp.?
Parsers VC has collected 19 articles mentioning Sarcomatrix Therapeutics, Corp., among them “Sarcomatrix Therapeutics Appoints Dr. Jeff Myers as Chief Medical Officer” (Jul 17, 2026) and “Sarcomatrix Therapeutics Corp. Opens Seed+ Investment Round to Accredited Investors on the KoreInside Platform” (Jul 15, 2026).
Is Sarcomatrix Therapeutics, Corp. still active?
Yes, Sarcomatrix Therapeutics, Corp. is active; its latest activity on Parsers VC dates from Jul 24, 2026.